Ivanics T, Rizzari M, Moonka D, et al. - Since a near‐universal cure for patients with chronic hepatitis C virus (HCV) infection and better outcomes following liver transplant (LT) has resulted from the success of direct‐acting antiviral (DAA) therapy, researchers examined the patterns and outcomes of retransplantation in HCV and non‐HCV patients before and after the introduction of DAA. Adult patients who had re‐LT were found in the Organ Procurement and Transplantation Network/United Network for Organ Sharing database. There were 2,112 re‐LT patients included in the study. It was noted that one‐year graft survival was 69.8% before DAA and 83.8% after DAA. Only HCV individuals with first graft loss due to disease recurrence exhibited the positive post‐DAA era effect. In the post‐DAA era, receiving a re‐LT was correlated with improved patient and graft survival among HCV patients.